| Schedule of Segment Reporting Information, by Segment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biopharmaceuticals |
|
Bioprocessing |
|
|
|
|
Year Ended June 30, 2022 (in thousands) |
|
iBio, Inc. |
|
iBio CDMO |
|
Eliminations |
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues - external customers |
|
$ |
1,884 |
|
$ |
499 |
|
$ |
— |
|
$ |
2,383 |
Revenues - intersegment |
|
|
1,586 |
|
|
2,455 |
|
|
(4,041) |
|
|
— |
Cost of goods sold |
|
|
— |
|
|
216 |
|
|
— |
|
|
216 |
Gross profit |
|
|
3,470 |
|
|
2,739 |
|
|
(4,041) |
|
|
2,167 |
Research and development |
|
|
11,819 |
|
|
8,260 |
|
|
(2,350) |
|
|
17,729 |
General and administrative |
|
|
20,844 |
|
|
14,975 |
|
|
(1,691) |
|
|
34,128 |
Operating loss |
|
|
(29,194) |
|
|
(20,496) |
|
|
— |
|
|
(49,690) |
Interest expense |
|
|
— |
|
|
(1,412) |
|
|
— |
|
|
(1,412) |
Forgiveness of note payable and accrued interest |
|
|
— |
|
|
607 |
|
|
— |
|
|
607 |
Interest and other income |
|
|
184 |
|
|
7 |
|
|
— |
|
|
191 |
Consolidated net loss |
|
|
(29,010) |
|
|
(21,295) |
|
|
— |
|
|
(50,305) |
Total assets |
|
|
156,893 |
|
|
43,092 |
|
|
(100,578) |
|
|
99,407 |
Finance lease ROU assets |
|
|
— |
|
|
74 |
|
|
— |
|
|
74 |
Operating lease ROU assets |
|
|
3,068 |
|
|
1,952 |
|
|
— |
|
|
5,020 |
Fixed assets, net of accumulated depreciation |
|
|
1,373 |
|
|
35,288 |
|
|
— |
|
|
36,661 |
Intangible assets, net of accumulated amortization |
|
|
4,851 |
|
|
— |
|
|
— |
|
|
4,851 |
Amortization of ROU assets |
|
|
— |
|
|
599 |
|
|
— |
|
|
599 |
Depreciation expense |
|
|
— |
|
|
2,275 |
|
|
— |
|
|
2,275 |
Amortization of intangible assets |
|
|
401 |
|
|
— |
|
|
— |
|
|
401 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biopharmaceuticals |
|
Bioprocessing |
|
|
|
|
Year Ended June 30, 2021 (in thousands) |
|
iBio, Inc. |
|
iBio CDMO |
|
Eliminations |
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues - external customers |
|
$ |
1,098 |
|
$ |
1,274 |
|
$ |
— |
|
$ |
2,371 |
Revenues - intersegment |
|
|
1,017 |
|
|
1,307 |
|
|
(2,324) |
|
|
— |
Cost of goods sold |
|
|
425 |
|
|
1,037 |
|
|
— |
|
|
1,462 |
Gross profit |
|
|
1,690 |
|
|
1,543 |
|
|
(2,324) |
|
|
909 |
Research and development |
|
|
2,960 |
|
|
8,370 |
|
|
(1,341) |
|
|
9,989 |
General and administrative |
|
|
13,429 |
|
|
9,585 |
|
|
(983) |
|
|
22,031 |
Operating loss |
|
|
(14,699) |
|
|
(16,412) |
|
|
— |
|
|
(31,111) |
Interest expense |
|
|
— |
|
|
(2,454) |
|
|
— |
|
|
(2,454) |
Settlement income |
|
|
10,200 |
|
|
— |
|
|
— |
|
|
10,200 |
Interest and royalty income |
|
|
151 |
|
|
1 |
|
|
— |
|
|
152 |
Consolidated net loss |
|
|
(4,349) |
|
|
(18,864) |
|
|
— |
|
|
(23,213) |
Total assets |
|
|
175,272 |
|
|
35,721 |
|
|
(64,025) |
|
|
146,968 |
Finance lease ROU assets |
|
|
— |
|
|
26,111 |
|
|
— |
|
|
26,111 |
Fixed assets, net of accumulated depreciation |
|
|
— |
|
|
8,628 |
|
|
— |
|
|
8,628 |
Intangible assets, net of accumulated amortization |
|
|
952 |
|
|
— |
|
|
— |
|
|
952 |
Amortization of finance lease ROU assets |
|
|
— |
|
|
1,651 |
|
|
— |
|
|
1,651 |
Depreciation expense |
|
|
— |
|
|
472 |
|
|
— |
|
|
472 |
Amortization of intangible assets |
|
|
291 |
|
|
— |
|
|
— |
|
|
291 |
|